Khavinson Bioregulators — Organ-Targeted Short Peptides

How the Khavinson system works

Every bioregulator here is a short peptide — two to four amino acids — that acts through organ-directed signaling: it reaches a specific tissue and modulates that tissue's gene expression at sub-nanomolar concentrations. That's a fundamentally different mechanism from the receptor agonists elsewhere in the catalog, and it's why the vials are small and the doses tiny. Each peptide came out of decades of Russian clinical and preclinical work.

Matching a bioregulator to its target organ

The whole shelf is organized by tissue, so you pick by what you want to support:

• Thymogen, Vilon — immune / thymus
• Cardiogen — cardiovascular
• Bronchogen, Chonluten — respiratory
• Prostamax, Testagen — reproductive
• Pancragen — pancreas / metabolic
• Pinealon, Adamax — brain / pineal
• Ovagen — liver
• Vesugen, Vesilute — vascular / urinary
• Cortagen, Crystagen, Livagen — cortex, immune and other regulatory targets

Why the vials look alike

Most of these ship in the same 20 mg vial at a near-uniform price, which throws people off. It's a feature of the class, not a catalog quirk: they're all short peptides made and dosed the same way, so the price reflects the format rather than the target. The difference between two Khavinson vials is which organ they signal, not their strength or scarcity.

Sub-nanomolar dosing

Because they act at such low concentrations, Khavinson protocols use far smaller effective doses than the receptor peptides on other shelves — which is why per-milligram comparisons against something like BPC-157 don't mean much. Reconstitute, store cold, and dose to the protocol for the specific bioregulator rather than by vial-size intuition.